Morphine Regulates Expression of m-Opioid Receptor MOR-1A, an Intron-Retention Carboxyl Terminal Splice Variant of the m-Opioid Receptor (OPRM1) Gene via miR-103/miR-107s

Molecular Pharmacology

Volumn 85, Issue 2, 2014, Pages 368-380

  Lu, Zhigang ^a   Xu, Jin ^a   Xu, Mingming ^a   Pasternak, Gavril W ^a   Pan, Ying Xian ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; MICRORNA 103; MICRORNA 107; MORPHINE; MU OPIATE RECEPTOR; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ALTERNATIVE RNA SPLICING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CELL STRAIN HEK293; CONTROLLED STUDY; CORPUS STRIATUM; DOWN REGULATION; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INTRON RETENTION; LUCIFERASE ASSAY; MALE; MORPHINE TOLERANCE; MOUSE; MU OPIATE RECEPTOR GENE; MUTAGENESIS; NONHUMAN; NORTHERN BLOTTING; POLYSOME; PRIORITY JOURNAL; RNA EXTRACTION; UPREGULATION;

EID: 84891879239     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.089292     Document Type: Article

References (66)

1. Abbadie C, Pan YX, Drake CT, and Pasternak GW (2000a) Comparative immunohistochemical distributions of carboxy terminus epitopes from the mu-opioid receptor splice variants MOR-1D, MOR-1 and MOR-1C in the mouse and rat CNS. Neuroscience 100:141-153.
2. Abbadie C, Pan YX, and Pasternak GW (2000b) Differential distribution in rat brain of mu opioid receptor carboxy terminal splice variants MOR-1C-like and MOR-1- like immunoreactivity: evidence for region-specific processing. J Comp Neurol 419: 244-256.
3. Abbadie C, Pasternak GW, and Aicher SA (2001) Presynaptic localization of the carboxy-terminus epitopes of the mu opioid receptor splice variants MOR-1C and MOR-1D in the superficial laminae of the rat spinal cord. Neuroscience 106: 833-842.
4. Bare LA, Mansson E, and Yang D (1994) Expression of two variants of the human mu opioid receptor mRNA in SK-N-SH cells and human brain. FEBS Lett 354: 213-216.
5. Baskerville S and Bartel DP (2005) Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. RNA 11:241-247.
6. Bolan EA, Pan YX, and Pasternak GW (2004) Functional analysis of MOR-1 splice variants of the mouse mu opioid receptor gene Oprm. Synapse 51:11-18.
7. Chen HY, Lin YM, Chung HC, Lang YD, Lin CJ, Huang J, Wang WC, Lin FM, Chen Z, and Huang HD et al. (2012) miR-103/107 promote metastasis of colorectal cancer by targeting the metastasis suppressors DAPK and KLF4. Cancer Res 72: 3631-3641.
8. Chen L, Chen XR, Chen FF, Liu Y, Li P, Zhang R, Yan K, Yi YJ, Xu ZM, and Jiang XD (2013) MicroRNA-107 inhibits U87 glioma stem cells growth and invasion. Cell Mol Neurobiol 33:651-657.
9. Dave RS and Khalili K (2010) Morphine treatment of human monocyte-derived macrophages induces differential miRNA and protein expression: impact on inflammation and oxidative stress in the central nervous system. J Cell Biochem 110: 834-845.
10. Dreyer JL (2010) New insights into the roles of microRNAs in drug addiction and neuroplasticity. Genome Med 2:92.
11. Elkon R, Ugalde AP, and Agami R (2013) Alternative cleavage and polyadenylation: extent, regulation and function. Nat Rev Genet 14:496-506.
12. Favereaux A, Thoumine O, Bouali-Benazzouz R, Roques V, Papon MA, Salam SA, Drutel G, Léger C, Calas A, and Nagy F et al. (2011) Bidirectional integrative regulation of Cav1.2 calcium channel by microRNA miR-103: role in pain. EMBO J 30:3830-3841.
13. Fortes P, Cuevas Y, Guan F, Liu P, Pentlicky S, Jung SP, Martinez-Chantar ML, Prieto J, Rowe D, and Gunderson SI (2003) Inhibiting expression of specific genes in mammalian cells with 59 end-mutated U1 small nuclear RNAs targeted to terminal exons of pre-mRNA. Proc Natl Acad Sci USA 100:8264-8269.
14. Giros B, Pohl M, Rochelle JM, and Seldin MF (1995) Chromosomal localization of opioid peptide and receptor genes in the mouse. Life Sci 56:PL369-PL375.
15. Goraczniak R, Behlke MA, and Gunderson SI (2009) Gene silencing by synthetic U1 adaptors. Nat Biotechnol 27:257-263.
16. Gunderson SI, Polycarpou-Schwarz M, and Mattaj IW (1998) U1 snRNP inhibits premRNA polyadenylation through a direct interaction between U1 70K and poly(A) polymerase. Mol Cell 1:255-264.
17. He Y, Yang C, Kirkmire CM, and Wang ZJ (2010) Regulation of opioid tolerance by let-7 family microRNA targeting the mu opioid receptor. J Neurosci 30:10251-10258.
18. Hwang CK, Wagley Y, Law PY, Wei LN, and Loh HH (2012) MicroRNAs in opioid pharmacology. J Neuroimmune Pharmacol 7:808-819.
19. Ide S, Han W, Kasai S, Hata H, Sora I, and Ikeda K (2005) Characterization of the 39 untranslated region of the human mu-opioid receptor (MOR-1) mRNA. Gene 364: 139-145.
20. Kaida D, Berg MG, Younis I, Kasim M, Singh LN, Wan L, and Dreyfuss G (2010) U1 snRNP protects pre-mRNAs from premature cleavage and polyadenylation. Nature 468:664-668.
21. Koch T, Schulz S, Pfeiffer M, Klutzny M, Schröder H, Kahl E, and Höllt V (2001) Cterminal splice variants of the mouse mu-opioid receptor differ in morphine-induced internalization and receptor resensitization. J Biol Chem 276:31408-31414.
22. Koch T, Schulz S, Schröder H, Wolf R, Raulf E, and Höllt V (1998) Carboxyl-terminal splicing of the rat mu opioid receptor modulates agonist-mediated internalization and receptor resensitization. J Biol Chem 273:13652-13657.
23. Kolesnikov YA, Pick CG, Ciszewska G, and Pasternak GW (1993) Blockade of tolerance to morphine but not to kappa opioids by a nitric oxide synthase inhibitor. Proc Natl Acad Sci USA 90:5162-5166.
24. Liang Y, Mestek A, Yu L, and Carr LG (1995) Cloning and characterization of the promoter region of the mouse mu opioid receptor gene. Brain Res 679:82-88.
25. Licatalosi DD and Darnell RB (2010) RNA processing and its regulation: global insights into biological networks. Nat Rev Genet 11:75-87.
26. Liu XY, Liu ZC, Sun YG, Ross M, Kim S, Tsai FF, Li QF, Jeffry J, Kim JY, and Loh HH et al. (2011) Unidirectional cross-activation of GRPR by MOR1D uncouples itch and analgesia induced by opioids. Cell 147:447-458.
27. Majumdar S, Burgman M, Haselton N, Grinnell S, Ocampo J, Pasternak AR, and Pasternak GW (2011a) Generation of novel radiolabeled opiates through siteselective iodination. Bioorg Med Chem Lett 21:4001-4004.
28. Majumdar S, Grinnell S, Le Rouzic V, Burgman M, Polikar L, Ansonoff M, Pintar J, Pan YX, and Pasternak GW (2011b) Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects. Proc Natl Acad Sci USA 108:19778-19783.
29. Mandel CR, Bai Y, and Tong L (2008) Protein factors in pre-mRNA 39-end processing. Cell Mol Life Sci 65:1099-1122.
30. Min BH, Augustin LB, Felsheim RF, Fuchs JA, and Loh HH (1994) Genomic structure analysis of promoter sequence of a mouse mu opioid receptor gene. Proc Natl Acad Sci USA 91:9081-9085.
31. Miska EA, Alvarez-Saavedra E, Townsend M, Yoshii A, Sestan N, Rakic P, Constantine- Paton M, and Horvitz HR (2004) Microarray analysis of microRNA expression in the developing mammalian brain. Genome Biol 5:R68.
32. Pan L, Xu J, Yu R, Xu MM, Pan YX, and Pasternak GW (2005a) Identification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene, Oprm. Neuroscience 133:209-220.
33. Pan YX (2005) Diversity and complexity of the mu opioid receptor gene: alternative pre-mRNA splicing and promoters. DNA Cell Biol 24:736-750.
34. Pan YX, Xu J, Mahurter L, Bolan E, Xu MM, and Pasternak GW (2001) Generation of the mu opioid receptor (MOR-1) protein by three new splice variants of the Oprm gene. Proc Natl Acad Sci USA 98:14084-14089.
35. Pan YX, Xu J, Bolan E, Abbadie C, Chang A, Zuckerman A, Rossi G, and Pasternak GW (1999) Identification and characterization of three new alternatively spliced mu-opioid receptor isoforms. Mol Pharmacol 56:396-403.
36. Pan YX, Xu J, Bolan E, Moskowitz HS, Xu M, and Pasternak GW (2005b) Identification of four novel exon 5 splice variants of the mouse mu-opioid receptor gene: functional consequences of C-terminal splicing. Mol Pharmacol 68:866-875.
37. Pan YX, Xu J, Xu M, Rossi GC, Matulonis JE, and Pasternak GW (2009) Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions. Proc Natl Acad Sci USA 106:4917-4922.
38. Pasternak DA, Pan L, Xu J, Yu R, Xu MM, Pasternak GW, and Pan YX (2004) Identification of three new alternatively spliced variants of the rat mu opioid receptor gene: dissociation of affinity and efficacy. J Neurochem 91:881-890.
39. Pasternak GW (1993) Pharmacological mechanisms of opioid analgesics. Clin Neuropharmacol 16:1-18.
40. Pasternak GW and Pan Y-X (2013) Mu opioids and their receptors: evolution of a concept. Pharmacol Rev 65:1257-1317.
41. Reisine T and Pasternak GW (1996) Opioid analgesics and antagonists, in Goodman & Gilman's: The Pharmacological Basis of Therapeutics 9th ed (Hardman JG and Limbird LE, eds) pp 521-556, McGraw-Hill, New York
42. Rossi GC, Brown GP, Leventhal L, Yang K, and Pasternak GW (1996) Novel receptor mechanisms for heroin and morphine-6 beta-glucuronide analgesia. Neurosci Lett 216:1-4.
43. Rossi GC, Leventhal L, Pan YX, Cole J, Su W, Bodnar RJ, and Pasternak GW (1997) antisense mapping of MOR-1 in rats: distinguishing between morphine and morphine- 6b-glucuronide antinociception. J Pharmacol Exp Ther 281:109-114.
44. Rossi GC, Pan Y-X, Brown GP, and Pasternak GW (1995) Antisense mapping the MOR-1 opioid receptor: evidence for alternative splicing and a novel morphine-6 beta-glucuronide receptor. FEBS Lett 369:192-196.
45. Rottiers V and Näär AM (2012) MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol 13:239-250.
46. Sanchez-Simon FM, Zhang XX, Loh HH, Law PY, and Rodriguez RE (2010) Morphine regulates dopaminergic neuron differentiation via miR-133b. Mol Pharmacol 78: 935-942.
47. Schuller AGP, King MA, Zhang JW, Bolan E, Pan YX, Morgan DJ, Chang A, Czick ME, Unterwald EM, and Pasternak GW et al. (1999) Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. Nat Neurosci 2:151-156.
48. Tanowitz M, Hislop JN, and von Zastrow M (2008) Alternative splicing determines the post-endocytic sorting fate of G-protein-coupled receptors. J Biol Chem 283: 35614-35621.
49. Tapocik JD, Luu TV, Mayo CL, Wang BD, Doyle E, Lee AD, Lee NH, and Elmer GI (2013) Neuroplasticity, axonal guidance and micro-RNA genes are associated with morphine self-administration behavior. Addict Biol 18:480-495.
50. Thoreen CC, Chantranupong L, Keys HR,Wang T, Gray NS, and Sabatini DM (2012) A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 485: 109-113.
51. Tian B and Manley JL (2013) Alternative cleavage and polyadenylation: the long and short of it. Trends Biochem Sci 38:312-320.
52. Tian B, Pan Z, and Lee JY (2007) Widespread mRNA polyadenylation events in introns indicate dynamic interplay between polyadenylation and splicing. Genome Res 17:156-165.
53. Trajkovski M, Hausser J, Soutschek J, Bhat B, Akin A, Zavolan M, Heim MH, and Stoffel M (2011) MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 474:649-653.
54. Vorlová S, Rocco G, Lefave CV, Jodelka FM, Hess K, Hastings ML, Henke E, and Cartegni L (2011) Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic polyA activation. Mol Cell 43:927-939.
55. Wang X and Wang X (2006) Systematic identification of microRNA functions by combining target prediction and expression profiling. Nucleic Acids Res 34:1646-1652.
56. Wang X, Ye L, Zhou Y, Liu MQ, Zhou DJ, and Ho WZ (2011) Inhibition of anti-HIV microRNA expression: a mechanism for opioid-mediated enhancement of HIV infection of monocytes. Am J Pathol 178:41-47.
57. Wilfred BR, Wang WX, and Nelson PT (2007) Energizing miRNA research: a review of the role of miRNAs in lipid metabolism, with a prediction that miR-103/107 regulates human metabolic pathways. Mol Genet Metab 91:209-217.
58. Wolozin BL and Pasternak GW (1981) Classification of multiple morphine and enkephalin binding sites in the central nervous system. Proc Natl Acad Sci USA 78: 6181-6185.
59. Wu J and Bag J (1998) Negative control of the poly(A)-binding protein mRNA translation is mediated by the adenine-rich region of its 59-untranslated region. J Biol Chem 273:34535-34542.
60. Wu Q, Hwang CK, Yao S, Law PY, Loh HH, and Wei LN (2005) A major species of mouse mu-opioid receptor mRNA and its promoter-dependent functional polyadenylation signal. Mol Pharmacol 68:279-285.
61. Wu Q, Hwang CK, Zheng H, Wagley Y, Lin HY, Kim K, Law PY, Loh HH, and Wei LN (2013) MicroRNA 339 down-regulates m-opioid receptor at the posttranscriptional level in response to opioid treatment. FASEB J 27:522-535.
62. Wu Q, Law PY, Wei LN, and Loh HH (2008) Post-transcriptional regulation of mouse mu opioid receptor (MOR1) via its 39 untranslated region: a role for microRNA23b. FASEB J 22:4085-4095.
63. Wu Q, Zhang L, Law PY, Wei LN, and Loh HH (2009) Long-term morphine treatment decreases the association of mu-opioid receptor (MOR1) mRNA with polysomes through miRNA23b. Mol Pharmacol 75:744-750.
64. Xu J, Xu M, Bolan E, Gilbert AK, Pasternak GW, and Pan Y-X (2013) Isolating and characterizing three alternatively spliced mu opioid receptor variants: mMOR-1A, mMOR-1O and mMOR-1P. Synapse, in press.
65. Zhang SY, Surapureddi S, Coulter S, Ferguson SS, and Goldstein JA (2012) Human CYP2C8 is post-transcriptionally regulated by microRNAs 103 and 107 in human liver. Mol Pharmacol 82:529-540.
66. Zheng H, Chu J, Zeng Y, Loh HH, and Law PY (2010) Yin Yang 1 phosphorylation contributes to the differential effects of mu-opioid receptor agonists on microRNA- 190 expression. J Biol Chem 285:21994-22002.